Yujuan Dong

Yujuan Dong

Auto-generated profile, based on publicly available information

Yujuan Dong

The Chinese University of Hong Kong, Hong Kong Special Administrative Region Department of Surgery, Faculty of Medicine, 999077

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
Wei KangWei Kang
Wei Kang
JZJinglin Zhang
Jinglin Zhang
THTingting Huang
Tingting Huang
YZYuhang Zhou
Yuhang Zhou
CWChi Chun Wong
Chi Chun Wong
Ka Fai ToKa Fai To
Ka Fai To
Aberrant Notch activation has been implicated in multiple malignancies and the identification of NOTCH receptors and related pathways is critical for targeted therapy. In this study, we aim to delineate the most prominent dysregulated NOTCH receptor and comprehensively reveal its deregulation in gastric cancer (GC). In the four Notch members, NOTCH3 was found uniformly upregulated and associated with poor clinical outcomes in multiple GC datasets. siRNA-mediated NOTCH3 knockdown demonstrated antitumor effects by suppressing cell proliferation, inhibiting monolayer formation, and impairing cell invasion abilities. Its depletion also induced early and late apoptosis. NOTCH3 was confirmed to be a direct target of two tumor suppressor microRNAs (miRNAs), namely miR-491-5p and miR-875-5p. The activation of NOTCH3 is partly due to the silence of these two miRNAs. Through RNA-seq profiling and functional validation, PHLDB2 was identified as a potent functional downstream modulator for NOTCH3 in gastric carcinogenesis. PHLDB2 expression demonstrated a positive correlation with NOTCH3, but was negatively correlated with miR-491-5p. Akt-mTOR was revealed as the downstream signaling of PHLDB2. The NOTCH3-PHLDB2-Akt co-activation was found in 33.7% GC patients and the activation of this axis predicted poor clinical outcome. GC cells treated with siNOTCH3, siPHLDB2, miR-491-5p, miR-875-5p, were more sensitive to Cisplatin and 5-FU. Taken together, the NOTCH3-PHLDB2-Akt cascade plays oncogenic role in gastric carcinogenesis and serves as a therapeutic target. Our study provided insights into Notch-mediated underlying molecular mechanisms and implied translational potential.

28 October 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
XWXiaohong Wang
Xiaohong Wang
LZLianhai Zhang
Lianhai Zhang
Jessie Qiaoyi LiangJessie Qiaoyi Liang
Jessie Qiaoyi Liang
CWChi Chun Wong
Chi Chun Wong
Huarong ChenHuarong Chen
Huarong Chen
JYJun Yu
Jun Yu
We elucidated the functional significance and molecular mechanisms of DUSP5P1 lncRNA (dual specificity phosphatase 5 pseudogene 1) in gastric carcinogenesis. We demonstrated that gastric cancer (GC) patients with high DUSP5P1 expression had shortened survival in two independent cohorts. DUSP5P1 promoted GC cell migration and invasion in vitro and metastasis in vivo. Mechanistically, DUSP5P1 activated ARHGAP5 transcription by directly binding to the promoter of ARHGAP5 with a binding motif of TATGTG. RNA-seq revealed that ARHGAP5 activated focal adhesion and MAPK signaling pathways to promote GC metastasis. DUSP5P1 also dysregulated platinum drug resistance pathway. Consistently, DUSP5P1 overexpression in GC cells antagonized cytotoxic effect of Oxaliplatin, and shDUSP5P1 plus Oxaliplatin exerted synergistic effect on inhibiting GC metastasis in vitro and in vivo. DUSP5P1 depletion also suppressed the growth of platinum drug-resistant PDO models. In conclusion, DUSP5P1 promoted GC metastasis by directly modulating ARHGAP5 expression to activate focal adhesion and MAPK pathways, serves as therapeutic target for platinum drug resistant GC, and is an independent prognostic factor in GC.

12 February 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
YZYan-An Zhou
Yan-An Zhou
NLNian-Shuang Li
Nian-Shuang Li
YZYu-Chen Zhu
Yu-Chen Zhu
ZHZe-Kun He
Ze-Kun He
YOYaobin Ouyang
Yaobin Ouyang
YHYi Hu
Yi Hu

17 September 2024 in Molecular Therapy
Verified
Journal Article
Open access
YDYujuan Dong
Yujuan Dong
JLJiaxun Jade Liu
Jiaxun Jade Liu
YZYunfei Zhou
Yunfei Zhou
WKWei Kang
Wei Kang
SLShanglin Li
Shanglin Li
JYJun Yu
Jun Yu
Immunoglobulin (Ig) VSTM2A (V-set and transmembrane domain containing 2A) is a top-ranked secretory protein frequently silenced during colorectal carcinogenesis; however, its role in immune modulation remains largely unknown. Bioinformatic and immunohistochemistry analysis of human colorectal specimens and Vstm2a+/- knockout mice indicated that VSTM2A positively correlated with CD8a and immune infiltration in both physiological and pathological conditions. We then utilized liquid chromatography-mass spectrometry to pinpoint programmed death ligand 1 (PD-L1) as a membrane receptor of VSTM2A. A series of in vitro biochemistry assays further revealed the binding pattern and kinetics between VSTM2A and PD-L1 proteins through their IgV domains at a dissociation constant of 0.7-2.5 nM. Recombinant VSTM2A protein inhibited the PD-1/PD-L1 interaction and induced NFAT response element (RE) luciferase activity dose dependently. Furthermore, interleukin (IL)-2 production from DO11.10 T cells upon co-culture with mouse non-T splenocytes was upregulated in the presence of VSTM2A conditioned medium. Finally, tumor killing assay and ex vivo data from human peripheral blood mononuclear cells and autologous dendritic cell-T cell co-culture demonstrated that VSTM2A significantly enhanced immune activation via the release of granzyme B and interferon (IFN)-γ cytokines. In conclusion, our study demonstrates the tumor-extrinsic role of VSTM2A in sterically blocking the PD-L1/PD-1 interaction at a picomole to nanomole affinity, which leads to the enhanced anti-tumor effect of cytotoxic T cells.

9 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SLStephen Li
Stephen Li
YDYujuan Dong
Yujuan Dong
JLJiaxun Liu
Jiaxun Liu
SLShanglin Li
Shanglin Li
DPDandan Pu
Dandan Pu
JWJason W. H. Wong
Jason W. H. Wong
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal form of liver cancer marked by high rates of tumor recurrence, posing substantial challenges to primary treatment options such as surgical resection and liver transplantation. Immunotherapy, which leverages T-cell-mediated recognition of tumor-specific antigens, has emerged as a promising alternative therapeutic strategy. While proteogenomics and ribosome profiling data across cancer types have provided growing evidence of active translation in non-canonical open reading frames (ncORFs), antigens derived from HCC-associated ncORFs remain largely unexplored. By integrating long-read and short-read RNA sequencing data with mass spectrometry, we have successfully identified twelve non-canonical peptides arising from cryptic translation of ncORFs. ELISpot assays confirmed cytokine release triggered by non-canonical peptides originating from distinct genomic loci. Subsequent RNA level analysis revealed four peptides with strong evidence of enriched expression in tumorigenesis. In-depth bioinformatics predictions indicate that these four peptides possess significant binding affinity for Major Histocompatibility Complex and T-Cell Receptor, with p2 emerging as the most promising candidate. Analysis using public datasets and experimental validation further highlighted the role of ribosome subunit recruitment and N6-Methyladenosine (m 6 A) modifications in enhancing translation initiation for tumor-enriched antigens. By addressing the existing shortage of knowledge in the HCC ncORF translation, this study identifies promising antigenic candidates for HCC immunotherapy, offering new avenues for effective treatment strategies and improved patient outcomes.

3 September 2025 in Cancer Research
Verified
Journal Article
Open access
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
LNLok Wan Ng
Lok Wan Ng
ZZZhongxu Zhu
Zhongxu Zhu
BCBonan Chen
Bonan Chen
SLStephen Li
Stephen Li
YDYujuan Dong
Yujuan Dong
Metabolic reprogramming, notably alterations in the tricarboxylic acid (TCA) cycle, has emerged as a hallmark of cancer that supports tumor growth and metastasis. Despite the TCA cycle being a classical central metabolic pathway, further exploration is needed to fully elucidate the intricate manifestations and contributory mechanisms of TCA cycle rewiring in colorectal carcinogenesis. In this study, we identified a splicing isoform of citrate synthase (CS), CS-ΔEx4, and unveiled its role in TCA cycle dysregulation in colorectal cancer. CS-ΔEx4 was distinctly upregulated in colorectal cancer tumors compared with the canonical CS full-length (CS-FL) isoform. Clinical analyses established a strong correlation between elevated CS-ΔEx4 expression and cancer recurrence as well as inferior survival outcomes in patients with colorectal cancer. Functional experiments revealed the active contribution of CS-ΔEx4 to the aggressive phenotype of colorectal cancer cells both in vitro and in vivo. Mechanistically, CS-ΔEx4 formed a heterocomplex with CS-FL within the mitochondria that influenced the enzymatic function of canonical CS and accelerated TCA cycle flux, thereby promoting the accumulation of the oncometabolite 2-hydroxyglutarate. The CS-ΔEx4–mediated metabolic alterations engendered epigenomic modulations that drove the upregulation of oncogenic gene signatures. In silico screening identified a small molecule with potent antiproliferative effects in colorectal cancer cell line and organoid models that selectively antagonized the CS-ΔEx4 and CS-FL heterocomplex activity while sparing the CS-FL homodimers. Together, this study discovered the presence of a spliced CS isoform that promotes colorectal cancer progression and identified a molecule that holds potential for targeting the CS-ΔEx4 and CS-FL heterocomplex. Significance: The citrate synthase variant CS-ΔEx4 augments TCA metabolic flux to facilitate epigenetic reprogramming and colorectal carcinogenesis and can be targeted with a small molecule, providing a promising treatment strategy for colorectal cancer. See related commentary by Schatton and Frezza, p. 4293